Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The B7441003 study will assess PF-06412562 for motor benefit in Parkinson's disease subjects. Safety, tolerability and PK of PF-06412562 in Parkinson's disease subjects will also be evaluated.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Male or female subjects with a diagnosis of idiopathic Parkinson's disease.

• Daily L-dopa dose between 300 and 1200 mg.

• MBRS score >1.

Exclusion Criteria:

• Surgical intervention for Parkinson's disease.

• History of troublesome dyskinesias.

• Any significant AXIS I psychiatric disease.